These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Securing the circuit of intrathecally administered cancer drugs: example of a collective approach. Marliot G; Le Rhun E; Sakji I; Bonneterre J; Cazin JL J Oncol Pharm Pract; 2011 Sep; 17(3):252-9. PubMed ID: 20525750 [TBL] [Abstract][Full Text] [Related]
3. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags. Gilbar PJ; Carrington CV J Oncol Pharm Pract; 2006 Jun; 12(2):113-8. PubMed ID: 16984750 [TBL] [Abstract][Full Text] [Related]
4. Drug delivery systems and combination therapy by using vinca alkaloids. Lee CT; Huang YW; Yang CH; Huang KS Curr Top Med Chem; 2015; 15(15):1491-500. PubMed ID: 25877096 [TBL] [Abstract][Full Text] [Related]
6. The Vincotube System: a design solution to prevent the accidental administration of intrathecal vinca alkaloids. Palmieri C; Barron N; Vigushin DM J Clin Oncol; 2004 Mar; 22(5):965; author reply 965-6. PubMed ID: 14990659 [No Abstract] [Full Text] [Related]
7. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Batra A; Patel B; Addison D; Baldassarre LA; Desai N; Weintraub N; Deswal A; Hussain Z; Brown SA; Ganatra S; Agarwala V; Parikh PM; Fradley M; Ghosh A; Guha A Open Heart; 2021 Dec; 8(2):. PubMed ID: 34952868 [TBL] [Abstract][Full Text] [Related]
8. [Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents]. Honda T; Sampi K; Hattori M Gan To Kagaku Ryoho; 1983 Nov; 10(11):2330-4. PubMed ID: 6639094 [TBL] [Abstract][Full Text] [Related]
9. Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. Kawada K; Ohta T; Fukuda H; Hayashi T; Tanaka K; Imai T; Morita Y; Miyamura M Ann Hematol; 2020 Oct; 99(10):2429-2436. PubMed ID: 32839869 [TBL] [Abstract][Full Text] [Related]
10. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Kang SP; Ratain MJ Clin Cancer Res; 2010 Sep; 16(17):4446-51. PubMed ID: 20736327 [TBL] [Abstract][Full Text] [Related]
11. A phase I trial of combination chemotherapy employing carboplatin vinca alkaloids, with or without bleomycin in patients with advanced malignant tumors. Einzig A Cancer Invest; 1990; 8(2):229-30. PubMed ID: 1698111 [No Abstract] [Full Text] [Related]
12. Pharmacokinetics and metabolism of vinca alkaloids. Rahmani R; Zhou XJ Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344 [TBL] [Abstract][Full Text] [Related]
14. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. Rivera MP; Kris MG; Gralla RJ; White DA Am J Clin Oncol; 1995 Jun; 18(3):245-50. PubMed ID: 7747713 [TBL] [Abstract][Full Text] [Related]
15. Revised physician labelling for neuroleptic drugs: Food and Drug Administration. Notice. Fed Regist; 1980 Aug; 45(155):52931-3. PubMed ID: 10314517 [TBL] [Abstract][Full Text] [Related]
16. Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs. Naci H; Guan X; Woloshin S; Xu Z; Wagner AK JAMA Intern Med; 2021 Nov; 181(11):1521-1522. PubMed ID: 34251420 [TBL] [Abstract][Full Text] [Related]
17. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs. Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878 [TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of intravenous vinzolidine. Taylor CW; Salmon SE; Satterlee WG; Robertone AB; McCloskey TM; Holdsworth MT; Plezia PM; Alberts DS Invest New Drugs; 1990; 8 Suppl 1():S51-7. PubMed ID: 2380017 [TBL] [Abstract][Full Text] [Related]